RheumaGen, Inc., a cell and gene therapy company engineering a new class of therapeutics to cure common autoimmune diseases, today announced groundbreaking preclinical research that supports a nearly ...

Solid Biosciences (($SLDB)) announced an update on their ongoing clinical study. Study Overview: Solid Biosciences is conducting a study titled A ...

A one-time gene therapy using a patient’s own stem cells has effectively cured a deadly immune disorder in 95% of treated ...

Medera Inc. ("Medera"), a clinical-stage biopharmaceutical company focused on targeting cardiovascular diseases by developing next-generation therapeutics, today announced that the first patient has ...

Solid Biosciences (($SLDB)) announced an update on their ongoing clinical study. Study Overview: Solid Biosciences is conducting a Phase 1b study ...

Fifteen-year-old Jayden Wilsey of Falmouth is the first person at Boston Children's Hospital to receive human gene therapy for sickle cell disease, following approval of the therapy in 2024 by the U.S ...

Results from MUSIC-HFpEF Phase 1/2a clinical trial show favorable safety profile and early clinical benefits with SRD-002 gene therapy BOSTON, May 19, 2025 (GLOBE NEWSWIRE) -- Medera Inc. (“Medera”), ...

Genprex, Inc. ("Genprex" or the "Company") (NASDAQ: GNPX), a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes, today announced ...

Gene therapy delivering protective vascular endothelial growth factor C into kidney filters reduced early diabetic kidney ...

Because the new method can replace a large stretch of defective DNA with a healthy sequence, the same retron-based package can fix any combination of mutations within that stretch of DNA without ...

An experimental gene therapy developed by researchers at UCLA, University College London and Great Ormond Street Hospital has ...